Vitrectomy with subretinal tissue plasminogen activator and ranibizumab for submacular haemorrhages secondary to age-related macular degeneration: retrospective case series of 45 consecutive cases – (Eye 30, 929 (July 2016))
Vitrectomy with subretinal tissue plasminogen activator and ranibizumab for submacular haemorrhages secondary to age-related macular degeneration: retrospective case series of 45 consecutive cases Eye 30, 929 (July 2016). doi:10.1038/eye.2016.65 Authors: J J González-López, G McGowan, E Chapman & D Yorston
Early-onset glaucoma in Axenfeld–Rieger anomaly: long-term surgical results and visual outcome – (Eye 30, 936 (July 2016))
Early-onset glaucoma in Axenfeld–Rieger anomaly: long-term surgical results and visual outcome Eye 30, 936 (July 2016). doi:10.1038/eye.2016.66 Authors: A K Mandal & N Pehere
Confidence of ophthalmology specialist trainees in the management of posterior capsule rupture and vitreous loss – (Eye 30, 943 (July 2016))
Confidence of ophthalmology specialist trainees in the management of posterior capsule rupture and vitreous loss Eye 30, 943 (July 2016). doi:10.1038/eye.2016.55 Authors: A M J Turnbull & S C Lash
Diagnosis of retinopathy in children younger than 12 years of age: implications for the diabetic eye screening guidelines in the UK – (Eye 30, 949 (July 2016))
Diagnosis of retinopathy in children younger than 12 years of age: implications for the diabetic eye screening guidelines in the UK Eye 30, 949 (July 2016). doi:10.1038/eye.2016.59 Authors: A Hamid, H M Wharton, A Mills, J M Gibson, M Clarke & P M Dodson
Early treatment of acute submacular haemorrhage secondary to wet AMD using intravitreal tissue plasminogen activator, C3F8, and an anti-VEGF agent – (Eye 30, 952 (July 2016))
Early treatment of acute submacular haemorrhage secondary to wet AMD using intravitreal tissue plasminogen activator, C3F8, and an anti-VEGF agent Eye 30, 952 (July 2016). doi:10.1038/eye.2016.67 Authors: S R de Silva & M S Bindra